Five9 Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Five9 Inc trades at $33.37 (market cap $2.65B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.9× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FIVN | GMED | |
|---|---|---|
Market Cap | $2.65B | $10.25B |
Volume | 971,747 | 1,108,124 |
Sector | Technology | Health |
52-Week High | $38.65 | $96.82 |
52-Week Low | $13.61 | $58.33 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.80B | $9.76B |
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.08, down 7.26% today amid recent volatility, though the stock remains near its 52-week high of $39.55. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and accelerating AI revenue growth reaching 78% year-over-year. Technical indicators suggest a bullish trend with moving averages supporting upside potential, while RSI levels remain neutral. Five9 maintains leadership in the contact center-as-a-service market with improving profitability margins.
The outlook remains positive with analyst consensus favoring Buy ratings (61%) and a $34 price target representing 3% upside. Key opportunities include AI revenue expansion and market leadership, while risks involve insider selling activity and competitive pressures in the CCaaS space. The company's transition to profitability and strong subscription growth support continued investor interest.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →